{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:46:28Z","timestamp":1792593988244,"version":"4.5.0"},"reference-count":60,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            This study assessed the clinical impact and cost\u2013effectiveness of switching from tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) in a Greek chronic hepatitis B (CHB) population.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            A Markov model from the perspective of a third-party payer in Greece quantified the health and economic benefits of switching from TDF to either TAF or ETV over a lifetime horizon.\n            <jats:bold>Results:<\/jats:bold>\n            Over a lifetime, patients who switch from TDF to TAF versus patients who switch from TDF to ETV had an overall lower incidence of compensated cirrhosis (0.4% lower), decompensated cirrhosis (0.04% lower) and hepatocellular carcinoma (0.25% lower). Chronic kidney disease and end-stage renal disease were also lower in patients who switch to TAF; major osteoporotic fractures were similar for both groups. While total costs were higher for switching from TDF to TAF versus TDF to ETV due to the higher cost of TAF, switching from TDF to TAF versus ETV was cost effective with an incremental cost\u2013effectiveness ratio of \u20ac17,113 per quality-adjusted life year.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Switching from TDF to TAF in patients living with CHB is a cost effective strategy to reduce adverse liver disease outcomes, while improving bone- and renal-related safety outcomes.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0090","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T08:36:12Z","timestamp":1707208572000},"source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2013effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece"],"prefix":"10.57264","volume":"13","author":[{"given":"Emmanouil","family":"Sinakos","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine, Hippokratio Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Kachru","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tsoulas","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"Maple Health Group, LLC, New York, NY\u00a010019, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J","family":"Smith","sequence":"additional","affiliation":[{"name":"Maple Health Group, LLC, New York, NY\u00a010019, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Yehoshua","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Medical School of National &amp; Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","unstructured":"World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection (2015). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305553\/pdf\/Bookshelf_NBK305553.pdf"},{"issue":"1","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault NA","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1), 261\u2013283 (2016).","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_8_5_2","first-page":"431","article-title":"The changing epidemiology of hepatitis B in Greece","volume":"34","author":"Rigopoulou EI","year":"2021","unstructured":"Rigopoulou EI, Gatselis NK, Galanis K The changing epidemiology of hepatitis B in Greece. Ann. Gastroenterol. 34(3), 431\u2013437 (2021).","journal-title":"Ann. Gastroenterol."},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejim.2020.05.013","article-title":"A surveillance study of the prevalence of Hepatitis B, C, and D markers among hospitalized patients at an Internal Medicine Department of a Greek Hospital","volume":"79","author":"Sevastianos VA","year":"2020","unstructured":"Sevastianos VA, Geladari CV, Voulgaris TA, Georgantoni AI, Andreadis EA. A surveillance study of the prevalence of Hepatitis B, C, and D markers among hospitalized patients at an Internal Medicine Department of a Greek Hospital. Eur. J. Intern. Med. 79, 142\u2013144 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"e_1_3_8_7_2","unstructured":"Dalekos GN Goulis I Manolakopoulos S Papaevangelous V Papatheodoridis GV. On behalf of the viral hepatitis scientific committee of the National Public Health Organization of Greece. Clinical practice guidelines on the management of hepatitis B virus infection (2017). https:\/\/eody.gov.gr\/wp-content\/uploads\/2019\/01\/Odigies-HBV-2017-final.pdf"},{"issue":"3","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial","volume":"1","author":"Chan HL","year":"2016","unstructured":"Chan HL, Fung S, Seto WK Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1(3), 185\u2013195 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial","volume":"1","author":"Buti M","year":"2016","unstructured":"Buti M, Gane E, Seto WK Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1(3), 196\u2013206 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.16788","article-title":"Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data","volume":"55","author":"Lim Y-S","year":"2022","unstructured":"Lim Y-S, Seto W-K, Kurosaki M Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment. Pharmacol. Ther. 55(8), 921\u2013943 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of hbsag seroclearance in adults with chronic HBV Infection: a systematic review and meta-analysis","volume":"156","author":"Yeo YH","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang H-I Factors associated with rates of hbsag seroclearance in adults with chronic HBV Infection: a systematic review and meta-analysis. Gastroenterology 156(3), 635\u2013646; e9 (2019).","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_8_12_2","first-page":"73","article-title":"Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs","volume":"34","author":"Siakavellas S","year":"2021","unstructured":"Siakavellas S, Goulis J, Manolakopoulos S Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. Ann. Gastroenterology 34(1), 73\u201379 (2021).","journal-title":"Ann. Gastroenterology"},{"issue":"3","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou K","year":"2019","unstructured":"Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol. Hepatol. 4(3), 227\u2013238 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"35","author":"Gu L","year":"2020","unstructured":"Gu L, Yao Q, Shen Z Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 35(9), 1467\u20131476 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis","volume":"14","author":"Li M","year":"2020","unstructured":"Li M, Lv T, Wu S Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol. Int. 14(1), 105\u2013114 (2020).","journal-title":"Hepatol. Int."},{"issue":"2","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","volume":"19","author":"Choi WM","year":"2021","unstructured":"Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 19(2), 246\u2013258; e9 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"9","author":"Liu H","year":"2020","unstructured":"Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis. Liver Cancer 9(4), 468\u2013476 (2020).","journal-title":"Liver Cancer"},{"issue":"1","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang Z","year":"2019","unstructured":"Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 19(1), 511 (2019).","journal-title":"BMC Cancer"},{"key":"e_1_3_8_19_2","volume-title":"The International Liver Congress.","author":"Huang Y","year":"2020","unstructured":"Huang Y, Yu M, Cheng P Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan. Presented at: The International Liver Congress. (27\u201329 August 2020)."},{"issue":"7","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis","volume":"69","author":"Lee SW","year":"2020","unstructured":"Lee SW, Kwon JH, Lee HL Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 69(7), 1301\u20131308 (2020).","journal-title":"Gut"},{"issue":"5","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir","volume":"66","author":"Shin JW","year":"2021","unstructured":"Shin JW, Jeong J, Jung SW Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir. Dig. Dis. Sci. 66(5), 1739\u20131750 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_8_22_2","unstructured":"Gilead Sciences Inc. Data on File. Tenofovir alafenamide. Week 48 data summary for studies GS-US-320-0108 and GUS-US-320-0110 (2016)."},{"issue":"50","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"e2276","DOI":"10.1097\/MD.0000000000002276","article-title":"Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study","volume":"94","author":"Chen CH","year":"2015","unstructured":"Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine 94(50), e2276 (2015).","journal-title":"Medicine"},{"issue":"5","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong TL","year":"2019","unstructured":"Fong TL, Lee BT, Tien A Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J. Viral Hepat. 26(5), 561\u2013567 (2019).","journal-title":"J. Viral Hepat."},{"key":"e_1_3_8_25_2","unstructured":"Foundation for Osteoporosis Research and Education. 10-year fracture risk calculator version 2.0. (2015). https:\/\/www.sheffield.ac.uk\/FRAX\/tool.aspx?country=9"},{"issue":"5","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"S1087","DOI":"10.1016\/S0016-5085(17)33665-X","article-title":"Longitudinal changes in renal function and comorbidities in treatment-naive and treatment-experienced chronic hepatitis B patients in an US insured population: analysis of a real-world cohort with long-term follow-up","volume":"52","author":"Liou I","year":"2017","unstructured":"Liou I, Nguyen MH, Lim JK Longitudinal changes in renal function and comorbidities in treatment-naive and treatment-experienced chronic hepatitis B patients in an US insured population: analysis of a real-world cohort with long-term follow-up. Gastroenterology 52(5), S1087\u2013S1088 (2017).","journal-title":"Gastroenterology"},{"issue":"6","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu YS","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35(6), 1522\u20131527 (2002).","journal-title":"Hepatology"},{"issue":"28","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta10280","article-title":"Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation","volume":"10","author":"Shepherd J","year":"2006","unstructured":"Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol. Assess. 10(28), iii\u2013iv; xi\u2013xiv, 1\u2013183 (2006). https:\/\/pubmed.ncbi.nlm.nih.gov\/16904047\/","journal-title":"Health Technol. Assess."},{"issue":"8","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","article-title":"Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B","volume":"13","author":"Dakin H","year":"2010","unstructured":"Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 13(8), 934\u2013945 (2010).","journal-title":"Value Health"},{"issue":"5","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen CJ","year":"2009","unstructured":"Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49(Suppl. 5), S72\u2013S84 (2009).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","article-title":"Natural history of hepatitis B","volume":"39","author":"Fattovich G","year":"2003","unstructured":"Fattovich G. Natural history of hepatitis B. J. Hepatol. 39(Suppl. 1), S50\u2013S58 (2003).","journal-title":"J. Hepatol."},{"issue":"7","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","article-title":"Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study","volume":"23","author":"Wu IT","year":"2017","unstructured":"Wu IT, Hu TH, Hung CH Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin. Microbiol. Infect. 23(7), 464\u2013469 (2017).","journal-title":"Clin. Microbiol. Infect."},{"issue":"8","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","author":"Iloeje UH","year":"2007","unstructured":"Iloeje UH, Yang HI, Jen CL Risk and predictors of mortality associated with chronic hepatitis B infection. Clin. Gastroenterol. Hepatol. 5(8), 921\u2013931 (2007).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283365356","article-title":"Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV","volume":"24","author":"Neuhaus J","year":"2010","unstructured":"Neuhaus J, Angus B, Kowalska JD Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 24(5), 697\u2013706 (2010).","journal-title":"AIDS"},{"key":"e_1_3_8_35_2","unstructured":"United States Renal Data System (USRDS). 2014 Annual Data Report. Volume 1: CKD. Chapter 3: Morbidity and Mortality (2014). https:\/\/www.niddk.nih.gov\/about-niddk\/strategic-plans-reports\/usrds\/prior-data-reports\/2014"},{"issue":"11","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.1968","article-title":"Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men","volume":"28","author":"Bliuc D","year":"2013","unstructured":"Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J. Bone Miner. Res. 28(11), 2317\u20132324 (2013).","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00019053-200725110-00006","article-title":"Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B","volume":"25","author":"Veenstra DL","year":"2007","unstructured":"Veenstra DL, Sullivan SD, Clarke L Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 25(11), 963\u2013977 (2007).","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"e9756","DOI":"10.1097\/MD.0000000000009756","article-title":"Effect of tenofovir on renal function in patients with chronic hepatitis B","volume":"97","author":"Jung WJ","year":"2018","unstructured":"Jung WJ, Jang JY, Park WY Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore) 97(7), e9756 (2018).","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_8_39_2","unstructured":"eurostat. Life table by age and sex (2019). https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/demo_mlifetable\/default\/table?lang=en"},{"issue":"3","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy AR","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 11(3), 527\u2013538 (2008).","journal-title":"Value Health"},{"key":"e_1_3_8_41_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-Reported Population Health: An International Perspective based on EQ-5D.","author":"Szende A","year":"2014","unstructured":"Szende A, Janssen B, Cabases J (Eds). Self-Reported Population Health: An International Perspective based on EQ-5D. Springer, The Netherlands (2014). https:\/\/pubmed.ncbi.nlm.nih.gov\/29787044\/"},{"issue":"2","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jbmr.4181","article-title":"Health service use and quality of life recovery 12 months following major osteoporotic fracture: latent class analyses of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)","volume":"36","author":"Talevski J","year":"2021","unstructured":"Talevski J, Sanders KM, Busija L Health service use and quality of life recovery 12 months following major osteoporotic fracture: latent class analyses of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). J. Bone Miner. Res. 36(2), 252\u2013261 (2021).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","article-title":"Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review","volume":"18","author":"Cooper JT","year":"2010","unstructured":"Cooper JT, Lloyd A, Sanchez JJG, S\u00f6rstadius E, Briggs A, McFarlane P. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health Qual. Life Outcomes 18(1), 310 (2010).","journal-title":"Health Qual. Life Outcomes"},{"key":"e_1_3_8_44_2","unstructured":"Moody's Analytics Economic Indicators. Greece \u2013 Consumer Price Index (CPI). https:\/\/www.economy.com\/greece\/consumer-price-index-cpi"},{"key":"e_1_3_8_45_2","unstructured":"OECD. Purchasing power parities. https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm"},{"issue":"1","key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom A","year":"2013","unstructured":"Svedbom A, Hernlund E, Iverg\u00e5rd M Osteoporosis in the European Union: a compendium of country-specific reports. Arch. Osteoporos 8(1), 137 (2013).","journal-title":"Arch. Osteoporos"},{"key":"e_1_3_8_47_2","unstructured":"Hellenic Association of Pharmaceutical Companies. Price Bulletin (2021). https:\/\/www.sfee.gr\/category\/topics\/market-access\/deltia-timon-farmakon-2021-en\/?lang=en"},{"issue":"7","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.clinthera.2015.05.003","article-title":"Boceprevir for chronic genotype 1 hepatitis C virus in the current health care setting in Greece: a cost\u2013effectiveness analysis","volume":"37","author":"Athanasakis K","year":"2015","unstructured":"Athanasakis K, Ferrante SA, Kyriopoulos II Boceprevir for chronic genotype 1 hepatitis C virus in the current health care setting in Greece: a cost\u2013effectiveness analysis. Clin. Ther. 37(7), 1529\u20131540 (2015).","journal-title":"Clin. Ther."},{"issue":"7","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"A496","DOI":"10.1016\/j.jval.2013.08.1108","article-title":"A cost-of-illness analysis of hepatitis C in Greece","volume":"16","author":"Athanasakis K","year":"2013","unstructured":"Athanasakis K, Arzoumanidou D, Petrakis I A cost-of-illness analysis of hepatitis C in Greece. Value Health 16(7), A496 (2013).","journal-title":"Value Health"},{"issue":"7","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/add.13764","article-title":"Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?","volume":"112","author":"Gountas I","year":"2017","unstructured":"Gountas I, Sypsa V, Anagnostou O Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction 112(7), 1290\u20131299 (2017).","journal-title":"Addiction"},{"issue":"1","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund E","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos 8(1), 136 (2013).","journal-title":"Arch. Osteoporos"},{"key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7175\/fe.v12i1.95","article-title":"The health and social costs of chronic kidney disease in Italy","volume":"12","author":"Cicchetti A","year":"2011","unstructured":"Cicchetti A, Ruggeri M, Codella P, Ridolfi A. The health and social costs of chronic kidney disease in Italy. Farmeconomia Health Econ. Ther. Path. 12, 21 (2011).","journal-title":"Farmeconomia Health Econ. Ther. Path."},{"issue":"1","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S0266462305050051","article-title":"Economic evaluation of hemodialysis: implications for technology assessment in Greece","volume":"21","author":"Kaitelidou D","year":"2005","unstructured":"Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL. Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int. J. Technol. Assess Health Care 21(1), 40\u201346 (2005).","journal-title":"Int. J. Technol. Assess Health Care"},{"issue":"1","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.healthpol.2007.10.002","article-title":"An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy","volume":"86","author":"Kontodimopoulos N","year":"2008","unstructured":"Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Pol. 86(1), 85\u201396 (2008).","journal-title":"Health Pol."},{"issue":"2","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5301\/ijao.5000477","article-title":"Cost calculations during \u201cdire straits\u201d: a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece","volume":"39","author":"Naoum P","year":"2016","unstructured":"Naoum P, Topkaroglou I, Kitsonis D Cost calculations during \u201cdire straits\u201d: a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece. Int. J. Artif. Organs 39(2), 87\u201389 (2016).","journal-title":"Int. J. Artif. Organs"},{"issue":"3","key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5604\/01.3001.0009.8590","article-title":"Cost\u2013effectiveness and clinical impact of antiviral strategies of HBeAg-positive and -negative chronic hepatitis B","volume":"16","author":"Oyag\u00fcez I","year":"2017","unstructured":"Oyag\u00fcez I, Buti M, Brosa M, Rueda M, Casado MA. Cost\u2013effectiveness and clinical impact of antiviral strategies of HBeAg-positive and -negative chronic hepatitis B. Ann. Hepatol. 16(3), 358\u2013365 (2017).","journal-title":"Ann. Hepatol."},{"issue":"3","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","author":"Choi J","year":"2020","unstructured":"Choi J, Kim GA, Han S, Lim YS. Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B. Am. J. Gastroenterol. 115(3), 406\u2013414 (2020).","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai CL","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011\u20131020 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_8_59_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2016.0040","article-title":"Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"23","author":"Lee KS","year":"2017","unstructured":"Lee KS, Kweon Y-O, Um S-H Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin. Mol. Hepatol. 23(4), 331\u2013339 (2017).","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"e_1_3_8_60_2","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials","volume":"98","author":"Cai D","year":"2019","unstructured":"Cai D, Pan C, Yu W Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials. Medicine (Baltimore) 98(1), e13983 (2019).","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"e_1_3_8_61_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2374-815X\/4\/5\/00198","article-title":"A cost of illness analysis of hepatitis B virus infection in Greece","volume":"4","author":"Athanasakis K","year":"2017","unstructured":"Athanasakis K, Pliarchopoulou F, Reppas L A cost of illness analysis of hepatitis B virus infection in Greece. J. Gastroenterol. Pancreatol. Liver Dis. 4(5), 1\u20133 (2017).","journal-title":"J. Gastroenterol. Pancreatol. Liver Dis."},{"issue":"4","key":"e_1_3_8_62_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/apt.17093","article-title":"HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and\/or bone disorders or risks","volume":"56","author":"Papatheodoridis GV","year":"2022","unstructured":"Papatheodoridis GV, Mimidis K, Manolakopoulos S HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and\/or bone disorders or risks. Aliment. Pharmacol. Ther. 56(4), 702\u2013712 (2022).","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:14:09Z","timestamp":1711113249000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.57264\/cer-2023-0090"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0090","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"article-number":"e230090"}}